The Technical Analyst
Q BioMed Inc. [QBIO]
Exchange: PNK Industry: Biotechnology
Q BioMed Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0005
America/New_York / 1 mai 2024 @ 15:43
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.0725 mill |
| EPS: | -0.0200 |
| P/E: | -0.0200 |
| Earnings Date: | May 26, 2024 |
| SharesOutstanding: | 145.10 mill |
| Avg Daily Volume: | 0.0237 mill |
| RATING 2024-05-01 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | |||||
| Gr.Profit | n/a | n/a | ||||
| Ebit | n/a | |||||
| Asset | n/a | |||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0200 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.0200 | industry: PE -107.25 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0005 - 0.0005 ( +/- 0.00%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-05-26 | Corin Denis | Buy | 200 000 | Common Stock |
| 2021-02-01 | Rosenstadt William S | Buy | 35 000 | Common stock |
| 2020-10-27 | Corin Denis | Buy | 500 000 | Incentive Stock Options |
| 2020-08-29 | Corin Denis | Buy | 150 000 | Incentive Stock Options |
| 2020-08-29 | Corin Denis | Buy | 150 000 | Incentive Stock Options |
| INSIDER POWER |
|---|
| 100.00 |
| Last 100 transactions |
| Buy: 7 488 702 | Sell: 150 251 |
Forecast:
16:00 - $0.0005
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.0005 (0.00% ) |
| Volume | 0.0207 mill |
| Avg. Vol. | 0.0237 mill |
| % of Avg. Vol | 87.12 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For QBIO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
QBIO
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutics to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.
Latest Press Releases
2021-09-28 08:00:00 - Press Release
Q Biomed Inc. Provides Update On Strontium89 Commercial Roll Out Revenue Up In 4th Quarter With Positive Trend
New york, sept. 28, 2021 /prnewswire/ -- q biomed inc. (otcqb: qbio) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, has seen an uptick in strontium89 (strontium chloride sr-89 injection, usp) sales starting its 4th quarter.
2021-09-22 08:30:00 - Press Release
Q Biomed Inc. Updates On Covid-19 Therapeutic Development And Clinical Trials - Man-19 Therapeutic Program Heading To Clinical Trial In Early 2022
New york, sept. 22, 2021 /prnewswire/ -- q biomed inc. (otcqb: qbio) a commercial stage biotechnology acceleration company, is pleased to provide an update on its partner asset man-19 for the treatment of acute respiratory distress syndrome (ards), a condition caused by viral infections in the lungs including covid-19.
2021-05-20 11:26:00 - Press Release
Q Biomed Engages Contract Sales Force With Deep Va And Oncology Experience
New york, may 20, 2021 /prnewswire/ -- q biomed inc. (otcqb: qbio), a commercial stage biotech company, announced today that it has hired wsi pbg, llc (wsi), a michigan based firm specializing in creating access for and selling pharmaceuticals, medical diagnostics and durable medical equipment in the veterans administration (va), military health system (mhs) and indian healthcare system (ihs). wsi will have 6 federal account managers promoting strontium89 (strontium chloride sr-89 injection, usp) within 76 va and mhs medical centers across the us.
2021-04-27 07:30:00 - Press Release
Q Biomed Updates Shareholders
New york, april 27, 2021 /prnewswire/ -- q biomed inc. (otcqb: qbio), a commercial stage biotech company, updates shareholders. in march 2021,it was announced that our technology partner, mannin research inc. (mannin), is receiving up to cad$1.7 million in research and development funding from the national research council of canada industrial research assistance program (nrc irap) to support the pre-clinical development of a therapeutic to treat acute respiratory distress syndrome in covid-19.
2021-01-27 07:30:00 - Press Release
Q Biomed's Uttroside-b Receives U.s. Fda Orphan Drug Designation In The Treatment Of Liver Cancer
New york, jan. 27, 2021 /prnewswire/ -- q biomed inc. (otcqb: qbio), announced today that the u.s. food and drug administration's office of orphan products development has granted orphan drug designation to uttroside-b, a small molecule chemotherapeutic for the treatment of hepatocellular...
Latest News
2023-04-14 09:05:15 - Proactive Investors
Q BioMed receives US patent and notice of allowance in Europe for Uttroside B; seeks ways to boost shareholder value
Q BioMed Inc. (OTCQB:QBIO) said it has received a patent in the US and a notice of allowance in Europe for the Uttroside B chemotherapeutic asset, adding to the already issued patents in Korea, Canada and Japan, which the company says shows tremendous value in the liver cancer market for the asset and which also has Orphan Drug designation from the US Food and Drug Administration (FDA). The biotech acceleration and commercial stage company said it has exclusive rights to the technology through an agreement with the Rajiv Gandhi Centre for Biotechnology, an Autonomous Institute under the Department of Biotechnology, Government of India, and the Oklahoma Medical Research Foundation.
2023-02-10 09:21:17 - Proactive Investors
Q BioMed gets notice of allowable US patent for liver cancer treatment Uttroside B
Q BioMed Inc. (OTCQB:QBIO) has received a notice of an allowable patent from the US Patent Office related to its liver cancer treatment Uttroside B. The company already holds patents in Korea, Canada and Japan, and Uttroside B previously received Orphan Drug designation from the US Food and Drug Administration.
2022-11-14 11:09:55 - Proactive Investors
Q BioMed boosted by multi-million dollar asset as it converts long-term royalty into equity stake in Mannin Research
Q BioMed Inc has given itself a big shot in the arm, adding a multi-million dollar asset in the form of an equity stake in long term partner Mannin Research, which has a drug development pipeline poised to be a multi-billion dollar blockbuster franchise for years to come. The company has converted its long-term royalty agreement into a 15% equity stake in private Mannin - a holding, which has a current valuation of C$30 million.
2022-09-27 09:46:22 - Proactive Investors
Q Biomed announces patent for groundbreaking GDF15 biomarker for glaucoma detection and treatment
Q BioMed Inc. (OTCQB:QBIO) said it has received a European Certificate of Grant for GDF15, a diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differentiation Factor 15 (GDF15) licensed from the Washington University in St. Louis, Missouri.
2022-07-29 10:43:47 - Proactive Investors
Q BioMed reports Strontium89 sales revenue surge in shareholder update
Q BioMed Inc said it has seen an uptick in sales revenue from Strontium89, the company's potential chemotherapeutic drug, in its recently reported quarter. The company's second-quarter sales revenue was nearly double its first-quarter figure, representing the company's best sales number to date.
2022-07-26 10:10:58 - Proactive Investors
Q BioMed says new publication shows superior safety and efficacy of Uttroside-B versus FDA approved drug Sorafenib
Q BioMed Inc has highlighted that its pre-clinical Uttroside-B chemotherapeutic to treat liver cancer has been found in a new study to show superior safety and efficacy compared to the current FDA approved drug Sorafenib. The publication in May this year was entitled 'Augmented Efficacy of Uttroside-B over Sorafenib in a Murine Model of Human Hepatocellular Carcinoma'.
2022-05-06 10:41:15 - Proactive Investors
Q BioMed says its strategy is paying off as it outlines its value proposition in multibillion-dollar markets
Q BioMed Inc told investors that it had studiously avoided biotech single-asset risks by acquiring multiple assets over time, across a broad spectrum of indications in large markets and its strategy was paying dividends. The New York-based company has a winner in cancer bone pain drug Strontium89 and a deep pipeline of biomedical assets.
2022-03-16 09:44:47 - Proactive Investors
Q BioMed announces publication of research supporting efficacy and development of its Uttroside-B chemotherapeutic to treat liver cancer
Q BioMed Inc. (OTCQB:QBIO) has announced a new publication in the Frontiers of Oncology journal supporting the efficacy and further development of its Uttroside-B (Utt-B) chemotherapeutic to treat liver cancer. In the initial Scientific Reports study, Q BioMed said researchers showed that in animal models Utt-B was 10 times more cytotoxic to the HepG2 liver cancer cell line than sorafenib, the only drug approved by the US Food and Drug Administration (FDA) for liver cancer.
2022-02-14 13:21:43 - Proactive Investors
Q BioMed outlines strategic direction and goals for 2022
Q BioMed Inc has outlined its strategic directions and goals for 2022 that call for increasing revenues as the biotech seeks to monetize its current pipeline of products and platforms. “From inception our goal has been to identify assets and advance them to a point where they can return value to our shareholders,” the company said in a statement.
2021-12-16 16:52:00 - Proactive Investors
Q BioMed says it is seeing a ‘significant uptrend' in revenues as it continues to roll out Strontium89
Q BioMed Inc. (OTCQB:QBIO) told shareholders that the company was seeing a significant uptrend in revenues, advancing its pipeline of assets, and was looking at an imminent up listing to the tech-dominated Nasdaq. The New York-based commercial-stage biotech company has engaged EVERSANA, which provides commercial services, to support the commercialization of Strontium89.